Palvella Therapeutics, Inc. Increase Decrease In Operating Lease Liability
Palvella Therapeutics, Inc. (PVLA) reported Increase Decrease In Operating Lease Liability of -$98.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOperatingLeaseLiability · last filed 2026-08-04
- Palvella Therapeutics, Inc. increase decrease in operating lease liability for the quarter ending 2026-06-30 was -$49.00K.
- Palvella Therapeutics, Inc. increase decrease in operating lease liability for the quarter ending 2026-03-31 was -$49.00K.
- Palvella Therapeutics, Inc. increase decrease in operating lease liability for the quarter ending 2025-06-30 was $0.00.
- Palvella Therapeutics, Inc. increase decrease in operating lease liability for the quarter ending 2025-03-31 was $0.00.
| Period end | Increase Decrease In Operating Lease Liability 3 month | Increase Decrease In Operating Lease Liability 6 month |
|---|---|---|
| 2026-06-30 | -$49.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | -$98.00K 10-Q · filed 2026-08-04 |
| 2026-03-31 | -$49.00K 10-Q · filed 2026-05-07 | |
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | $0.00 10-Q · filed 2026-08-04 |
| 2025-03-31 | $0.00 10-Q · filed 2026-05-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |